HIF1? is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 41, 2013, Pages 16568-16573

  Miyauchi, Yoshiteru ^a,b   Sato, Yuiko ^a,c   Kobayashi, Tami ^a,d   Yoshida, Shigeyuki ^e   Mori, Tomoaki ^a   Kanagawa, Hiroya ^a   Katsuyama, Eri ^a   Fujie, Atsuhiro ^a   Hao, Wu ^a   Miyamoto, Kana ^a,d   Tando, Toshimi ^a   Morioka, Hideo ^a   Matsumoto, Morio ^a   Chambon, Pierre ^f   Johnson, Randall S ^g   Kato, Shigeaki ^h   Toyama, Yoshiaki ^a   Miyamoto, Takeshi ^a,b,d  

^a Department of Orthopedic Surgery ^*  (United States)

^b Integrated Bone Metabolism and Immunology   (Japan)

^c Musculoskeletal Reconstruction and Regeneration Surgery   (United States)

^d Keio Kanrinmaru Project   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h Soma Central Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; 2-METHOXYESTRADIOL; HIF1A PROTEIN, MOUSE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INACTIVATION; ESTROGEN DEFICIENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN STABILITY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CROSS BREEDING; DEFICIENCY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GENOTYPE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; METABOLISM; NICK END LABELING; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; DRUG ANTAGONISM; DRUG EFFECT;

ADMINISTRATION, ORAL; ANIMALS; CELLS, CULTURED; CROSSES, GENETIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; ESTROGENS; FEMALE; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; MICE; MICE, KNOCKOUT; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; POLYMERASE CHAIN REACTION;

EID: 84885336550     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1308755110     Document Type: Article

References (24)

1. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359(9322): 2018-2026.
2. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289(5484):1508-1514.
3. Nelson ER, Wardell SE, McDonnell DP (2013) The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis. Bone 53(1):42-50.
4. Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators-Mechanisms of action and application to clinical practice. N Engl J Med 348(7):618-629.
5. Couse JF, Korach KS (1999) Estrogen receptor null mice: What have we learned and where will they lead us? Endocr Rev 20(3):358-417.
6. Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295(5564):2465-2468.
7. Schipani E, et al. (2001) Hypoxia in cartilage: HIF-1α is essential for chondrocyte growth arrest and survival. Genes Dev 15(21):2865-2876.
8. Wang Y, et al. (2007) The hypoxia-inducible factor α pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 117(6):1616-1626.
9. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148(3): 399-408.
10. Koh MY, Spivak-Kroizman TR, Powis G (2008) HIF-1 regulation: Not so easy come, easy go. Trends Biochem Sci 33(11):526-534.
11. Ryan HE, et al. (2000) Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 60(15):4010-4015.
12. Ahluwalia A, Tarnawski AS (2012) Critical role of hypoxia sensor-HIF-1α in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem 19(1):90-97.
13. Liao D, Johnson RS (2007) Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26(2):281-290.
14. Andrikopoulou E, et al. (2011) Current insights into the role of HIF-1 in cutaneous wound healing. Curr Mol Med 11(3):218-235.
15. Keith B, Johnson RS, Simon MC (2012) HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12(1):9-22.
16. Maes C, Carmeliet G, Schipani E (2012) Hypoxia-driven pathways in bone development, regeneration and disease. Nat Rev Rheumatol 8(6):358-366.
17. Miyamoto T, et al. (2000) An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. Blood 96(13):4335-4343.
18. Fujita N, et al. (2008) Vascular endothelial growth factor-A is a survival factor for nucleus pulposus cells in the intervertebral disc. Biochem Biophys Res Commun 372(2): 367-372.
19. Nakamura T, et al. (2007) Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130(5):811-823.
20. Mabjeesh NJ, et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3(4):363-375.
21. Arjamaa O, Nikinmaa M (2006) Oxygen-dependent diseases in the retina: Role of hypoxia-inducible factors. Exp Eye Res 83(3):473-483.
22. Dupont S, et al. (2000) Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127(19):4277-4291.
23. Yagi M, et al. (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202(3):345-351.
24. Miyauchi Y, et al. (2010) The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 207(4):751-762.